EGFR and non-small cell lung carcinoma: The initial pre-clinical evidence connecting MET to resistance against third-generation EGFR TKIs came from observations regarding an EGFR-mutant NSCLC cell line, HCC827/ER, with acquired resistance to erlotinib.